BMS

News
BMS_Nassau_Park

BMS confirms Taisho’s $1.6bn offer for UPSA

After protracted speculation, Bristol-Myers Squibb has confirmed it plans to divest its French over-the-counter (OTC) medicines business UPSA to Japan’s Taisho Pharma in a $1.6 billion deal